Michail_Petrov-96
- As the American Diabetes Association’s 84th Scientific Sessions wraps up Monday, two key players in the diabetes treatment space are trading down.
- In early afternoon trading, Tandem Diabetes Care (NASDAQ:TNDM) is down ~6%, while DexCom (NASDAQ:DXCM) is off ~4%.
- Both companies made presentations at the conference. Tandem released results from a quality of life survey from users of its Tandem Mobi insulin pump. Meanwhile, DexCom released additional data on the benefits of its continuous glucose monitors.
- In addition, Insulet (PODD) released positive results from the pivotal SECURE-T2D trial on the Omnipod 5 insulin delivery system. Shares are trading flat.
- In a note, Oppenheimer noted that the planned August launch of DexCom’s over-the-counter CGM, Stelo, should be a driver for the company.
- The Tandem and DexCom declines could be a reaction to positive phase 2 data released this morning on Altimmune’s (ALT) weight loss candidate, pemvidutide.